Jefferies analyst Brian Abrahams provides insight on shares of Gilead Sciences, Inc. (NASDAQ:GILD) on the heels of hosting a dinner with a leading infectious disease specialist involved in patient care and preclinical/clinical research in a university health system considered the largest Boston HIV care provider.
In reaction, the analyst reiterates a Buy rating on shares of GILD with a $91 price target, which represents a 15% increase from where the stock is currently trading.
The specialist explained a potential rival to GILD might be rising with biotech firm ViiV Healthcare, who following the elimination of HIV drug abacavir, might come back in the role of competitor, particularly “given abacavir’s CV baggage and need for HLA testing.”
Additionally, the specialist expressed to Abrahams his optimism about the biotech giant’s pipeline drugs HIV-integrase inhibitor drug bictegravir, HIV infection and chronic hepatitis B- treating drug tenofovir alafenamide (TAF), and HIV-attacking oral capsule emtriva, which the specialist “views as an optimal cocktail.” The specialist has positive expectations going forward with GILD’s ongoing trials.
Moreover, Abrahams notes the specialist indicated, “Epidemiology and limited eradication promise support sustainability of HIV market long-term,” and therefore, “there will continue to be a need for GILD’s viral suppression regimens.”
“We came out remaining confident in GILD’s HIV life cycle strategies, and despite competition worth watching, the likelihood they will maintain their HIV revenues LT. We continue to believe HIV sustainability and potential pipeline upside are underappreciated,” he concludes.
As usual, we like to include the analyst’s track record when reporting on new analyst notes to give a perspective on the effect it has on stock performance. According to TipRanks, four-star analyst Brian Abrahams is ranked #731 out of 4,143 analysts. Abrahams has a 50% success rate and yields 3.6% in his annual returns. When recommending GILD, Abrahams earns 19.3% in average profits on the stock.
TipRanks analytics show GILD as a Buy. Based on 17 analysts polled in the last 3 months, 10 rate a Buy on GILD, while 7 maintain a Hold. The 12-month average price target stands at $107.04, marking a nearly 36% upside from where the shares last closed.